id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333738-3xtb8gye	Rabets, A.	Development of antibodies to pan-coronavirus spike peptides in convalescent COVID-19 patients	2020-08-22		.txt	text/plain	2486	146	49	Investigating patient serum samples after SARS-CoV-2 infection in cross-reactivity studies of immunogenic peptides from Middle East respiratory syndrome coronavirus (MERS-CoV), we were able to detect the production of antibodies also recognizing MERS virus antigens. Indeed, the peptide of the HR2 domain of the MERS spike protein, previously proven to induce antibodies against MERS-CoV is sharing 74% homology with the corresponding sequence of SARS-CoV-19 virus. If used as an antigen, the peptide of the HR2 domain of the MERS spike protein allows discrimination between post-Covid populations from non-infected ones by the presence of antibodies in blood samples. The high homology of the spike protein domain suggests in addition that the opposite effect can also be true: coronaviral infections producing cross-reactive antibodies affective against SARS-CoV-19. SARS-CoV-2 infections results in the generation of antibodies with significantly strong cross-reactive towards a MERS specific peptide with 76% homology. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein	./cache/cord-333738-3xtb8gye.txt	./txt/cord-333738-3xtb8gye.txt